Exploiting herpes simplex virus entry for novel therapeutics

Viruses

Volumn 5, Issue 6, 2013, Pages 1447-1465

  Hadigal, Satvik ^a   Shukla, Deepak ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

AC 8; Apolipoprotein E; Aptamers; Compound SP 510 50; Dendrimers; Dermaseptins; Endocytosis; Entry; Fusion; G1 and G2; gB; gD; gH gL; Hemifusion; Herpes; HSV 1; HSV 2; K 5 compounds; Nanoparticles; Peptides; PI3K inhibitor; Therapeutics; Viral glycoproteins; Viral surfing

Indexed keywords

ACICLOVIR; ANTIMICROBIAL CATIONIC PEPTIDE; APOLIPOPROTEIN E; APTAMER; BEHENYL ALCOHOL; CECROPIN A; CELLULOSE SULFATE; CYANOVIRIN N; DEFENSIN; DENDRIMER; DERMASEPTIN; GLYCOPROTEIN D; GLYCOPROTEIN L; GOLD NANOPARTICLE; HEPARAN SULFATE; INDOLICIDIN; MAGAININ 1; MAGAININ 2; MELITTIN; MICROBICIDE; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; POLYSTYRENESULFONIC ACID; PRO 2000; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRIFLURIDINE; UNINDEXED DRUG; VIVAGEL; ZINC OXIDE;

ANTIVIRAL ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG CYTOTOXICITY; DRUG TARGETING; ENDOCYTOSIS; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MEMBRANE FUSION; NONHUMAN; REVIEW; VIRAL CLEARANCE; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HUMANS; SIMPLEXVIRUS; VIRUS INTERNALIZATION;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 84878992111     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v5061447     Document Type: Review

References (99)

1. Whitley, R.J.; Herpesviruses. In Medical Microbiology, 4th ed.; Baron, S., Ed.; University of Texas Medical Branch at Galveston: Galveston, TX, USA, 1996; Chapter 68.
2. Ball, M.J. Limbic predilection in Alzheimer dementia: Is reactivated herpesvirus involved? Can. J. Neurol. Sci. 1982, 9, 303-306.
3. Nahmias, A.J.; Lee, F.K.; Beckman-Nahmias, S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. Suppl. 1990, 69, 19-36.
4. Heldwein, E.E.; Krummenacher, C. Entry of herpesviruses into mammalian cells. Cell Mol. Life Sci. 2008, 65, 1653-1668.
5. Willis, S.H.; Rux, A.H.; Peng, C.; Whitbeck, J.C.; Nicola, A.V.; Lou, H.; Hou, W.; Salvador, L.; Eisenberg, R.J.; Cohen, G.H. Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J. Virol. 1998, 72, 5937-5947.
6. Razonable, R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 2011, 86, 1009-1026.
7. Gerber, S.I.; Belval, B.J.; Herold, B.C. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. Virology 1995, 214, 29-39.
8. Cheshenko, N.; Herold, B.C. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J. Gen. Virol. 2002, 83, 2247-2255.
9. Herold, B.C.; Gerber, S.I.; Belval, B.J.; Siston, A.M.; Shulman, N. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J. Virol. 1996, 70, 3461-3469.
10. Herold, B.C.; Visalli, R.J.; Susmarski, N.; Brandt, C.R.; Spear, P.G. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J. Gen. Virol. 1994, 75, 1211-1222.
11. Herold, B.C.; WuDunn, D.; Soltys, N.; Spear, P.G. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J. Virol. 1991, 65, 1090-1098.
12. Spear, P.G.; Longnecker, R. Herpesvirus entry: An update. J. Virol. 2003, 77, 10179-10185.
13. Svitkina, T.M.; Bulanova, E.A.; Chaga, O.Y.; Vignjevic, D.M.; Kojima, S.; Vasiliev, J.M.; Borisy, G.G. Mechanism of filopodia initiation by reorganization of a dendritic network. J. Cell Biol. 2003, 160, 409-421.
14. Oh, M.J.; Akhtar, J.; Desai, P.; Shukla, D. A role for heparan sulfate in viral surfing. Biochem. Biophys. Res. Commun. 2010, 391, 176-181.
15. Nobes, C.D.; Hall, A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81, 53-62.
16. Connolly, S.A.; Jackson, J.O.; Jardetzky, T.S.; Longnecker, R. Fusing structure and function: A structural view of the herpesvirus entry machinery. Nat. Rev. Microbiol. 2011, 9, 369-381.
17. Karasneh, G.A.; Shukla, D. Herpes simplex virus infects most cell types in vitro: Clues to its success. Virol. J. 2011, 8, 481.
18. Gianni, T.; Amasio, M.; Campadelli-Fiume, G. Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. J. Biol. Chem. 2009, 284, 17370-17382.
19. Atanasiu, D.; Whitbeck, J.C.; Cairns, T.M.; Reilly, B.; Cohen, G.H.; Eisenberg, R.J. Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc. Natl. Acad. Sci. USA 2007, 104, 18718-18723.
20. Campadelli-Fiume, G.; Cocchi, F.; Menotti, L.; Lopez, M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev. Med. Virol. 2000, 10, 305-319.
21. Spear, P.G.; Eisenberg, R.J.; Cohen, G.H. Three classes of cell surface receptors for alphaherpesvirus entry. Virology 2000, 275, 1-8.
22. Krummenacher, C.; Supekar, V.M.; Whitbeck, J.C.; Lazear, E.; Connolly, S.A.; Eisenberg, R.J.; Cohen, G.H.; Wiley, D.C.; Carfi, A. Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J. 2005, 24, 4144-4153.
23. Fusco, D.; Forghieri, C.; Campadelli-Fiume, G. The pro-fusion domain of herpes simplex virus glycoprotein D (gD) interacts with the gD N terminus and is displaced by soluble forms of viral receptors. Proc. Natl. Acad. Sci. USA 2005, 102, 9323-9328.
24. Lazear, E.; Carfi, A.; Whitbeck, J.C.; Cairns, T.M.; Krummenacher, C.; Cohen, G.H.; Eisenberg, R.J. Engineered disulfide bonds in herpes simplex virus type 1 gD separate receptor binding from fusion initiation and viral entry. J. Virol. 2008, 82, 700-709.
25. Hutchinson, L.; Browne, H.; Wargent, V.; Davis-Poynter, N.; Primorac, S.; Goldsmith, K.; Minson, A.C.; Johnson, D.C. A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J. Virol. 1992, 66, 2240-2250.
26. Cairns, T.M.; Landsburg, D.J.; Whitbeck, J.C.; Eisenberg, R.J.; Cohen, G.H. Contribution of cysteine residues to the structure and function of herpes simplex virus gH/gL. Virology 2005, 332, 550-562.
27. Peng, T.; Ponce-de-Leon, M.; Jiang, H.; Dubin, G.; Lubinski, J.M.; Eisenberg, R.J.; Cohen, G.H. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J. Virol. 1998, 72, 65-72.
28. Avitabile, E.; Forghieri, C.; Campadelli-Fiume, G. Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: The interaction between gB and gH/gL does not necessarily require gD. J. Virol. 2009, 83, 10752-10760.
29. Subramanian, R.P.; Geraghty, R.J. Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. Proc. Natl. Acad. Sci. USA 2007, 104, 2903-2908.
30. Jackson, J.O.; Longnecker, R. Reevaluating herpes simplex virus hemifusion. J. Virol. 2010, 84, 11814-11821.
31. Jackson, J.O.; Lin, E.; Spear, P.G.; Longnecker, R. Insertion mutations in herpes simplex virus 1 glycoprotein H reduce cell surface expression, slow the rate of cell fusion, or abrogate functions in cell fusion and viral entry. J. Virol. 2010, 84, 2038-2046.
32. Gianni, T.; Cerretani, A.; Dubois, R.; Salvioli, S.; Blystone, S.S.; Rey, F.; Campadelli-Fiume, G. Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection. J. Virol. 2010, 84, 4013-4025.
33. Gianni, T.; Gatta, V.; Campadelli-Fiume, G. {alpha}V{beta}3-integrin routes herpes simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin2. Proc. Natl. Acad. Sci. USA 2010, 107, 22260-22265.
34. Atanasiu, D.; Saw, W.T.; Cohen, G.H.; Eisenberg, R.J. Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J. Virol. 2010, 84, 12292-12299.
35. Bzik, D.J.; Fox, B.A.; DeLuca, N.A.; Person, S. Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: Mutations affecting rate of virus entry and cell fusion. Virology 1984, 137, 185-190.
36. Heldwein, E.E.; Lou, H.; Bender, F.C.; Cohen, G.H.; Eisenberg, R.J.; Harrison, S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006, 313, 217-220.
37. Atanasiu, D.; Whitbeck, J.C.; de Leon, M.P.; Lou, H.; Hannah, B.P.; Cohen, G.H.; Eisenberg, R.J. Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J. Virol. 2010, 84, 3825-3834.
38. Smith, A.E.; Helenius, A. How viruses enter animal cells. Science 2004, 304, 237-242.
39. Milne, R.S.; Nicola, A.V.; Whitbeck, J.C.; Eisenberg, R.J.; Cohen, G.H. Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J. Virol. 2005, 79, 6655-6663.
40. Nicola, A.V.; McEvoy, A.M.; Straus, S.E. Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J. Virol. 2003, 77, 5324-5332.
41. Nicola, A.V.; Straus, S.E. Cellular and viral requirements for rapid endocytic entry of herpes simplex virus. J. Virol. 2004, 78, 7508-7517.
42. Clement, C.; Tiwari, V.; Scanlan, P.M.; Valyi-Nagy, T.; Yue, B.Y.; Shukla, D. A novel role for phagocytosis-like uptake in herpes simplex virus entry. J. Cell Biol. 2006, 174, 1009-1021.
43. Marsh, M.; Bron, R. SFV infection in CHO cells: Cell-type specific restrictions to productive virus entry at the cell surface. J. Cell Sci. 1997, 110, 95-103.
44. Wittels, M.; Spear, P.G. Penetration of cells by herpes simplex virus does not require a low pH-dependent endocytic pathway. Virus Res. 1991, 18, 271-290.
45. Treister, N.S.; Woo, S.B. Topical n-docosanol for management of recurrent herpes labialis. Expert Opin. Pharmacother. 2010, 11, 853-860.
46. Pope, L.E.; Marcelletti, J.F.; Katz, L.R.; Lin, J.Y.; Katz, D.H.; Parish, M.L.; Spear, P.G. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antivir. Res. 1998, 40, 85-94.
47. Shukla, D.; Spear, P.G. Herpesviruses and heparan sulfate: An intimate relationship in aid of viral entry. J. Clin. Invest. 2001, 108, 503-510.
48. Dobson, C.B.; Sales, S.D.; Hoggard, P.; Wozniak, M.A.; Crutcher, K.A. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J. Infect. Dis 2006, 193, 442-450.
49. Berdugo, M.; Larsen, I.V.; Abadie, C.; Deloche, C.; Kowalczuk, L.; Touchard, E.; Dubielzig, R.; Brandt, C.R.; Behar-Cohen, F.; Combette, J.M. Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application. Antimicrob. Agents Chemother. 2012, 56, 1390-1402.
50. Lass, J.H.; Langston, R.H.; Foster, C.S.; Pavan-Langston, D. Antiviral medications and corneal wound healing. Antivir. Res. 1984, 4, 143-157.
51. Bunka, D.H.; Platonova, O.; Stockley, P.G. Development of aptamer therapeutics. Curr. Opin. Pharmacol. 2010, 10, 557-562.
52. James, W. Nucleic acid and polypeptide aptamers: A powerful approach to ligand discovery. Curr. Opin. Pharmacol. 2001, 1, 540-546.
53. Khati, M.; Schuman, M.; Ibrahim, J.; Sattentau, Q.; Gordon, S.; James, W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J. Virol. 2003, 77, 12692-12698.
54. Moore, M.D.; Cookson, J.; Coventry, V.K.; Sproat, B.; Rabe, L.; Cranston, R.D.; McGowan, I.; James, W. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: Implications for RNA-based therapeutics. J. Biol. Chem. 2011, 286, 2526-2535.
55. Wang, J.; Jiang, H.; Liu, F. In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA 2000, 6, 571-583.
56. Gopinath, S.C.; Hayashi, K.; Kumar, P.K. Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry. J. Virol. 2012, 86, 6732-6744.
57. Moore, M.D.; Bunka, D.H.; Forzan, M.; Spear, P.G.; Stockley, P.G.; McGowan, I.; James, W. Generation of neutralizing aptamers against herpes simplex virus type 2: Potential components of multivalent microbicides. J. Gen. Virol. 2011, 92, 1493-1499.
58. Para, M.F.; Parish, M.L.; Noble, A.G.; Spear, P.G. Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions. J. Virol. 1985, 55, 483-488.
59. Mor, A.; Nguyen, V.H.; Delfour, A.; Migliore-Samour, D.; Nicolas, P. Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. Biochemistry 1991, 30, 8824-8830.
60. Amiche, M.; Ladram, A.; Nicolas, P. A consistent nomenclature of antimicrobial peptides isolated from frogs of the subfamily Phyllomedusinae. Peptides 2008, 29, 2074-2082.
61. Nicolas, P.; El Amri, C. The dermaseptin superfamily: A gene-based combinatorial library of antimicrobial peptides. Biochim. Biophys. Acta 2009, 1788, 1537-1550.
62. Belaid, A.; Aouni, M.; Khelifa, R.; Trabelsi, A.; Jemmali, M.; Hani, K. In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. J. Med. Virol. 2002, 66, 229-234.
63. Bergaoui, I.; Zairi, A.; Tangy, F.; Aouni, M.; Selmi, B.; Hani, K. In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2. J. Med. Virol. 2013, 85, 272-281.
64. Yaron, S.; Rydlo, T.; Shachar, D.; Mor, A. Activity of dermaseptin K4-S4 against foodborne pathogens. Peptides 2003, 24, 1815-1821.
65. Albiol Matanic, V.C.; Castilla, V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int. J. Antimicrob. Agents 2004, 23, 382-389.
66. Daher, K.A.; Selsted, M.E.; Lehrer, R.I. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 1986, 60, 1068-1074.
67. Wachinger, M.; Kleinschmidt, A.; Winder, D.; von Pechmann, N.; Ludvigsen, A.; Neumann, M.; Holle, R.; Salmons, B.; Erfle, V.; Brack-Werner, R. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J. Gen. Virol. 1998, 79, 731-740.
68. Hancock, R.E.; Chapple, D.S. Peptide antibiotics. Antimicrob. Agents Chemother. 1999, 43, 1317-1323.
69. Cheshenko, N.; Keller, M.J.; MasCasullo, V.; Jarvis, G.A.; Cheng, H.; John, M.; Li, J.H.; Hogarty, K.; Anderson, R.A.; Waller, D.P. et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 2004, 48, 2025-2036.
70. Jones, L.S.; Yazzie, B.; Middaugh, C.R. Polyanions and the proteome. Mol. Cell Proteomics 2004, 3, 746-769.
71. WuDunn, D.; Spear, P.G. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 1989, 63, 52-58.
72. Antoine, T.E.; Mishra, Y.K.; Trigilio, J.; Tiwari, V.; Adelung, R.; Shukla, D. Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. Antivir. Res. 2012, 96, 363-375.
73. Trigilio, J.; Antoine, T.E.; Paulowicz, I.; Mishra, Y.K.; Adelung, R.; Shukla, D. Tin oxide nanowires suppress herpes simplex virus-1 entry and cell-to-cell membrane fusion. PLoS One 2012, 7, e48147.
74. Baram-Pinto, D.; Shukla, S.; Richman, M.; Gedanken, A.; Rahimipour, S.; Sarid, R. Surface-modified protein nanospheres as potential antiviral agents. Chem. Commun. (Camb.) 2012, 48, 8359-8361.
75. Baram-Pinto, D.; Shukla, S.; Gedanken, A.; Sarid, R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small 2010, 6, 1044-1050.
76. Freeman, E.E.; Weiss, H.A.; Glynn, J.R.; Cross, P.L.; Whitworth, J.A.; Hayes, R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20, 73-83.
77. Vicenzi, E.; Gatti, A.; Ghezzi, S.; Oreste, P.; Zoppetti, G.; Poli, G. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS 2003, 17, 177-181.
78. Lindahl, U.; Li, J.P.; Kusche-Gullberg, M.; Salmivirta, M.; Alaranta, S.; Veromaa, T.; Emeis, J.; Roberts, I.; Taylor, C.; Oreste, P. et al. Generation of neoheparin from E. coli K5 capsular polysaccharide. J. Med. Chem. 2005, 48, 349-352.
79. Pinna, D.; Oreste, P.; Coradin, T.; Kajaste-Rudnitski, A.; Ghezzi, S.; Zoppetti, G.; Rotola, A.; Argnani, R.; Poli, G.; Manservigi, R. et al. Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob. Agents Chemother. 2008, 52, 3078-3084.
80. Epstein, S.P.; Nurozler, M.; Smetana, C.R.; Asbell, P.A. Efficacy of polyclonal antibodies for treatment of ocular herpes simplex infection. Cornea 2001, 20, 495-500.
81. Heegaard, P.M.; Boas, U. Dendrimer based anti-infective and anti-inflammatory drugs. Recent Pat. Antiinfect. Drug Discov. 2006, 1, 331-351.
82. Rosa Borges, A.; Schengrund, C.L. Dendrimers and antivirals: A review. Curr. Drug Targets Infect. Disord. 2005, 5, 247-254.
83. Menjoge, A.R.; Kannan, R.M.; Tomalia, D.A. Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov. Today 2010, 15, 171-185.
84. Gong, E.; Matthews, B.; McCarthy, T.; Chu, J.; Holan, G.; Raff, J.; Sacks, S. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antivir. Res. 2005, 68, 139-146.
85. Bernstein, D.I.; Stanberry, L.R.; Sacks, S.; Ayisi, N.K.; Gong, Y.H.; Ireland, J.; Mumper, R.J.; Holan, G.; Matthews, B.; McCarthy, T. et al. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 2003, 47, 3784-3788.
86. McGowan, I.; Gomez, K.; Bruder, K.; Febo, I.; Chen, B.A.; Richardson, B.A.; Husnik, M.; Livant, E.; Price, C.; Jacobson, C. et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011, 25, 1057-1064.
87. O'Loughlin, J.; Millwood, I.Y.; McDonald, H.M.; Price, C.F.; Kaldor, J.M.; Paull, J.R. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): A dose ranging, phase I study. Sex. Transm. Dis. 2010, 37, 100-104.
88. Chen, M.Y.; Millwood, I.Y.; Wand, H.; Poynten, M.; Law, M.; Kaldor, J.M.; Wesselingh, S.; Price, C.F.; Clark, L.J.; Paull, J.R. et al. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis. J. Acquir. Immune Defic. Syndr. 2009, 50, 375-380.
89. Tarallo, R.; Carberry, T.P.; Falanga, A.; Vitiello, M.; Galdiero, S.; Galdiero, M.; Weck, M. Dendrimers functionalized with membrane-interacting peptides for viral inhibition. Int. J. Nanomedicine 2013, 8, 521-534.
90. Luganini, A.; Nicoletto, S.F.; Pizzuto, L.; Pirri, G.; Giuliani, A.; Landolfo, S.; Gribaudo, G. Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers. Antimicrob. Agents Chemother. 2011, 55, 3231-3239.
91. Vo, T.S.; Ngo, D.H.; Ta, Q.V.; Kim, S.K. Marine organisms as a therapeutic source against herpes simplex virus infection. Eur. J. Pharm. Sci. 2011, 44, 11-20.
92. Tiwari, V.; Darmani, N.A.; Yue, B.Y.; Shukla, D. In vitro antiviral activity of neem (Azardirachta indica L.) bark extract against herpes simplex virus type-1 infection. Phytother. Res. 2010, 24, 1132-1140.
93. Tiwari, V.; Shukla, S.Y.; Shukla, D. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion. Antivir. Res. 2009, 84, 67-75.
94. Radtke, K.; Dohner, K.; Sodeik, B. Viral interactions with the cytoskeleton: A hitchhiker's guide to the cell. Cell Microbiol. 2006, 8, 387-400.
95. Lehmann, M.J.; Sherer, N.M.; Marks, C.B.; Pypaert, M.; Mothes, W. Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells. J. Cell Biol. 2005, 170, 317-325.
96. Sherer, N.M.; Lehmann, M.J.; Jimenez-Soto, L.F.; Horensavitz, C.; Pypaert, M.; Mothes, W. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat. Cell Biol. 2007, 9, 310-315.
97. Coffer, P.J.; Jin, J.; Woodgett, J.R. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 1998, 335, 1-13.
98. Tiwari, V.; Shukla, D. Phosphoinositide 3 kinase signalling may affect multiple steps during herpes simplex virus type-1 entry. J. Gen. Virol. 2010, 91, 3002-3009.
99. Lairson, D.R.; Begley, C.E.; Reynolds, T.F.; Wilhelmus, K.R. Prevention of herpes simplex virus eye disease: A cost-effectiveness analysis. Arch. Ophthalmol. 2003, 121, 108-112.